$Dermata Therapeutics (DRMA.US)$
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Monday, 16th December at 9:00 am
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -
SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ: DRMA)(NASDAQ: DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on t...

$Dermata Therapeutics (DRMA.US)$ fda approvsl news but stock not moved. anything missing here

$Rezolve AI (RZLV.US)$ Fall from 2.57 to 1.5++ after the announcement of partnership with Microsoft.

$Rezolve AI (RZLV.US)$ is this stock worth

$Super Micro Computer (SMCI.US)$ 32